Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study
Angela Toss(University of Modena and Reggio Emilia), Nicoleta Zenovia Antone(Institute of Oncology Prof. Dr. Ion Chiricuta), Fedro A. Peccatori(European Institute of Oncology), Fabio Puglisi(University of Udine), Rossella Graffeo(Ente Ospedaliero Cantonale), Natalia Cichowska-Cwalińska(Gdańsk Medical University), Zoe Kemp(Cancer Research UK), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Katarzyna Pogoda(Unknown), Laura De Marchis(Policlinico Umberto I), Pedro A. Meireles, Ana Krivokuća(Oncology Institute of Vojvodina), Eva Blondeaux(Ospedale Policlinico San Martino), Thomas Renaud(Institut Bergonié), Ava Kwong(University of Hong Kong), Bela Mriňáková(Comenius University Bratislava), Antonio Di Meglio(Inserm), Alberta Ferrari(University of Pavia), Cynthia Villarreal‐Garza(Johns Hopkins University), Jennifer K. Plichta(Cancer Institute (WIA)), Maiko Okano(Fukushima Medical University Hospital), Cristian Micheri(Instituto Argentino de Diagnóstico y Tratamiento), Kelly‐Anne Phillips(The University of Melbourne), Alexios Matikas(Karolinska University Hospital), Elena Tenedini(University of Modena and Reggio Emilia), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), H C F Moore(Cleveland Clinic), Hans Wildiers(KU Leuven), Caterina Gianni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), L Livraghi(Ospedale di Prato Santo Stefano), Christine Rousset‐Jablonski(Université Claude Bernard Lyon 1), Leonor Matos, Robert Fruscio(Azienda Ospedaliera San Gerardo), Rinat Yerushalmi(Rabin Medical Center), Wanyuan Cui(The University of Melbourne), Lucia Del Mastro(Ospedale Policlinico San Martino), Maria Del Pilar Estevez-Diz(International Organization for Migration), Elisa Agostinetto(Université Libre de Bruxelles), Judith Balmañà(Vall d'Hebron Hospital Universitari), Maira Caleffi(Hospital Moinhos de Vento), Rinat Bernstein‐Molho(Tel Aviv University), Michael Lee(Memorial Sloan Kettering Cancer Center), A. Parokonnaya(Russian Cancer Research Center NN Blokhin), Fergus J. Couch(Mayo Clinic), Lia Bonamici(University of Modena and Reggio Emilia), Yara Abdou(University of North Carolina at Chapel Hill), M Mariño-Mariño(Hospital Universitario Son Espases), Shani Paluch–Shimon(Hebrew University of Jerusalem)
Cited by 3
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k